Related Experiment Video
Updated: Aug 21, 2026
A Spheroid Killing Assay by CAR T Cells
Published on: December 12, 2018
[High-dose treatment with autologous stem cell support in a Norwegian region]
Jens Hammerstrøm1, Irene Line Aasland, Ragnar Telhaug
1St. Olavs Hospital, 7600 Trondheim. jens.hammerstrom@medisin.ntnu.no
Background:
The introduction of high-dose treatment with autologous stem cell support (HMAS) in Norwegian regional hospitals in the early 1990s was controversial. Concerns that low numbers of patients would lead to unacceptably low quality were expressed.
Material And Methods:
We present treatment results in the health region of Middle Norway, based on nearly 10 years of experience and 100 treated patients. Myeloma results are compared to the results from other Norwegian regional hospitals.
Results And Interpretation:
Overall survival for multiple myeloma after HMAS (median 6.8 years) was not significantly different in middle Norway compared to the rest of the country, and comparable with published results. Treatment-related mortality was low (1.2%). Results and complications in malignant lymphoma, breast cancer or germ cell tumours are described. HMAS can be satisfactorily given in a regional hospital with relatively few patients.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...